Reprint
Cardiovascular and Metabolic Disease: New Treatment and Future Directions
Edited by
June 2023
210 pages
- ISBN978-3-0365-7879-8 (Hardback)
- ISBN978-3-0365-7878-1 (PDF)
This book is a reprint of the Special Issue Cardiovascular and Metabolic Disease: New Treatment and Future Directions that was published in
Biology & Life Sciences
Medicine & Pharmacology
Summary
The present Special Issue will lead you to discover the association between cardiovascular and metabolic diseases, through update reviews and original articles exploring the pathophysiological mechanisms underpinning this association and describing the latest results in term of cardiovascular event prevention. An interesting scientific journey that reflects the recent advances in pharmacological treatments and interventional procedures.
Format
- Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
low-density lipoprotein receptor; apolipoprotein E; hyperglycemia; type 2 diabetes; Western diet; diabetes mellitus; GPCRs; GPR26; monocytes; peripheral blood cells; hyperglycemia; metabolomics; diabetes; N-Acetyl asparagine; QTc; cardiac fibrosis; scar tissue; anti-fibrotic therapies; cardiovascular diseases; myofibroblasts; nitric oxide synthase uncoupling; sapropterin; diabetic nephropathy; atrial fibrillation; hyperthyroidism; warfarin; ischemic stroke; transient ischemic attack; diabetes mellitus; transplant; complications; mortality; outcome; glucose metabolism; body mass index; metabolic syndrome; breast arterial calcifications; cardiovascular risk; mammograms; risk assessment; prevention; cost effectiveness; cardiac autonomic neuropathy; diabetes; oxidative stress; inflammation; endothelium dysfunction; direct oral anticoagulant; stroke prevention; atrial fibrillation; elderly; frail; malignancy; extreme weight; bioprosthetic valve; endocannabinoid system; CB1 cannabinoid receptor; diabetes; metabolic disease; metabolic syndrome; type 2 diabetes; non-alcoholic fatty liver disease; sodium-glucose cotransporter inhibitors; metformin; FibroScan®; controlled attenuation parameter; type 2 diabetes mellitus; heart failure; hemodynamics; dapagliflosin; adropin; natriuretic peptide